Literature DB >> 1591056

Long-term prognostic significance of thymidine labelling index in primary breast cancer.

T G Cooke1, P D Stanton, J Winstanley, G D Murray, R Croton, S Holt, W D George.   

Abstract

Tumour growth rates, as measured by incorporation of tritiated thymidine, have been reported as being of prognostic importance in breast cancer. We have measured the thymidine labelling index (TLI) of 185 early breast cancers, followed-up for a minimum of 8 years. Above median TLI was associated with higher tumour grade, but not with other prognostic factors. TLI was not predictive of survival in either univariate or multivariate analysis. The inter- and intra-observer reproducibilities of TLI measurements were poor, which may be a factor limiting its usefulness as a prognostic indicator in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1591056     DOI: 10.1016/s0959-8049(05)80067-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

Review 1.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

2.  Prospective evaluation of cell kinetics in head and neck squamous carcinoma: the relationship to tumour factors and survival.

Authors:  L D Cooke; T G Cooke; G Forster; A S Jones; P M Stell
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

3.  Is the thymidine labeling index a good prognostic marker in breast cancer?

Authors:  Ebru Sen-Oran; Vahit Ozmen; Ayhan Bilir; Neslihan Cabioglu; Mahmut Muslumanoglu; Abdullah Igci; Nese Guney; Mustafa Kecer
Journal:  World J Surg Oncol       Date:  2007-08-19       Impact factor: 2.754

4.  Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.

Authors:  Sian M Tovey; Caroline J Witton; John M S Bartlett; Peter D Stanton; Jonathan R Reeves; Timothy G Cooke
Journal:  Breast Cancer Res       Date:  2004-03-23       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.